Purpose The efficacy and safety of glucagon-like peptide (GLP)-1 receptor agonists for
weight loss in adult patients without diabetes is reviewed. Summary GLP-1 receptor agonists …

Purpose Published data on the weight loss effects of glucagon-like peptide 1 (GLP-1)
receptor agonists are reviewed, with a focus on data from clinical trials. Summary Obesity is …

Objective: To review the use of GLP-1 agonists in patients with type 1 diabetes mellitus
(T1DM). Data Sources: A search using the MEDLINE database, EMBASE, and Cochrane …

The aim of the work was to investigate whether continuation of treatment, side effects, and
effect on weight loss of GLP-1 agonists in obese patients without diabetes are equally …

OBJECTIVE: To review the efficacy and safety of liraglutide 3.0 mg for weight loss. DATA
SOURCE: A literature search was performed using PubMed and MEDLINE from 2000 to …

Clinical trials have investigated the weight loss effect of glucagon‐like peptide‐1 receptor
agonists (GLP‐1 RA) in adults with obesity without diabetes mellitus, but results for weight …

The prevalence of obesity has increased dramatically in recent decades, both in the US and
worldwide. Pharmacotherapy can augment the weight-reducing effects of lifestyle …

Overweight and obesity seriously damages human health. The World Health Organization
estimates that 1.5 billion adults were overweight in the year of 2011. Of this overweight …

Aim We investigated the relationship between weight change and related factors in subjects
with type 2 diabetes mellitus (T2DM) treated with liraglutide versus comparator diabetes …

Objective: Having demonstrated short-term weight loss with liraglutide in this group of obese
adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for …